keyword
MENU ▼
Read by QxMD icon Read
search

Dry eye treatment

keyword
https://www.readbyqxmd.com/read/28821553/epidemiology-of-discordance-between-symptoms-and-signs-of-dry-eye
#1
Erin S Ong, Elizabeth R Felix, Roy C Levitt, William J Feuer, Constantine D Sarantopoulos, Anat Galor
BACKGROUND/AIMS: The frequent lack of association between dry eye (DE) symptoms and signs leads to challenges in diagnosing and assessing the disease. METHODS: Participants underwent ocular surface examinations to evaluate signs of disease and completed questionnaires to assess ocular symptoms, psychological status and medication use. To assess nociceptive system integrity, quantitative sensory testing (QST), including vibratory and thermal threshold measures and temporal summation of pain were obtained at the forearm and forehead...
August 18, 2017: British Journal of Ophthalmology
https://www.readbyqxmd.com/read/28811936/real-life-management-of-patients-with-retinal-vein-occlusion-using-i-macula-web-platform
#2
Massimo Nicolò, Monica Bonetto, Raffaella Rosa, Donatella Musetti, Maria Musolino, Carlo Enrico Traverso, Mauro Giacomini
AIM: Real-life evaluation in the management of patients affected by macular edema secondary to retinal vein occlusion. MATERIAL AND METHODS: A retrospective, observational study using the I-Macula Web platform. RESULTS: Thirty-five patients (37 eyes; 15 females and 20 male) affected by RVO were analysed. At 12 months, there was a statistically significant improvement of best-corrected visual acuity (p = 0.0235) and central macular thickness (p < 0...
2017: Journal of Ophthalmology
https://www.readbyqxmd.com/read/28811095/can-the-optimum-artificial-tear-treatment-for-dry-eye-disease-be-predicted-from-presenting-signs-and-symptoms
#3
Laika Essa, Deborah Laughton, James S Wolffsohn
PURPOSE: To assess dry eye treatment with four preservative-free dry eye artificial tear treatments to facilitate evidence-based prescribing. METHODS: A randomised, single masked crossover trial of Clinitas Soothe, Hyabak, Tears Again and TheraTears artificial tears was conducted on 50 symptomatic dry eye patients, aged 60.8±14.2years. At baseline and after trialling each treatment for 4 weeks, signs and symptoms were assessed using the Ocular Surface Disease Index (OSDI), non-invasive tear break-up time, fluorescein tear break-up time, tear meniscus height (TMH), Phenol Red test, lid-parallel conjunctival folds (LIPCOF), ocular surface staining, and lipid layer grading and osmolarity (baseline visit only)...
August 12, 2017: Contact Lens & Anterior Eye: the Journal of the British Contact Lens Association
https://www.readbyqxmd.com/read/28791607/treatment-of-dry-eye-disease-with-autologous-platelet-rich-plasma-a-prospective-interventional-non-randomized-study
#4
Jorge L Alio, Alejandra E Rodriguez, Renan Ferreira-Oliveira, Dominika Wróbel-Dudzińska, Ahmed A Abdelghany
INTRODUCTION: The objective of this study was to evaluate the use of autologous platelet-rich plasma (PRP) eye drops as monotherapy for the treatment of moderate to severe cases of dry eye disease. METHODS: Three hundred and sixty-eight patients with moderate to severe dry eye disease (DED) were included in this prospective case series. Subjects were classified as evaporative DED (EDED) or aqueous deficient DED (ADDED). Improvement of the DED subjective symptoms, corneal fluorescein staining (CFS), and corrected distance visual acuity (BCVA) were evaluated...
August 8, 2017: Ophthalmology and Therapy
https://www.readbyqxmd.com/read/28790801/intense-pulsed-light-for-evaporative-dry-eye-disease
#5
REVIEW
Steven J Dell
There is a clear association between dry eye disease (DED) and skin inflammatory diseases occurring in close proximity to the eyelids, such as facial skin rosacea. Intense pulsed light (IPL) is widely accepted as a treatment for skin rosacea. A number of recent studies demonstrated that, in patients suffering from meibomian gland dysfunction (MGD), IPL therapy also reduces signs and symptoms of DED. Despite these encouraging results, in the context of DED and MGD, the mechanisms of action of IPL are not well understood...
2017: Clinical Ophthalmology
https://www.readbyqxmd.com/read/28782783/poly-%C3%AE%C2%B5-caprolactone-nanocapsule-carriers-with-sustained-drug-release-single-dose-for-long-term-glaucoma-treatment
#6
Chih-Hung Lee, Yu-Jia Li, Chih-Ching Huang, Jui-Yang Lai
Glaucoma is an eye-related disease accompanied by highly elevated intraocular pressure (IOP), which causes damage to the optic nerve and results in vision loss and even blindness. Although the treatment of glaucoma with eye drops may reduce the IOP, eye drops have some limitations, such as poor patient compliance and short duration. To develop drug carriers that facilitate the sustained and long-term release of drugs for glaucoma therapy, we synthesized poly(ε-caprolactone) nanoparticles (PCL NPs) capable of loading pilocarpine, a widely used drug for the treatment of dry eye and glaucoma...
August 7, 2017: Nanoscale
https://www.readbyqxmd.com/read/28777385/efficacy-of-eyedrops-containing-cross-linked-hyaluronic-acid-and-coenzyme-q10-in-treating-patients-with-mild-to-moderate-dry-eye
#7
Elisa I Postorino, Laura Rania, Emanuela Aragona, Carmen Mannucci, Angela Alibrandi, Gioacchino Calapai, Domenico Puzzolo, Pasquale Aragona
PURPOSE: Dry eye disease (DED) is a common condition causing substantial burden. A randomized, controlled, single-masked study was performed in 40 patients with mild to moderate DED to evaluate the efficacy and safety of a collyrium based on crosslinked hyaluronic acid (XLHA) with coenzyme Q10 (CoQ10). METHODS: Enrolled subjects were divided into 2 groups: group A, treated with XLHA + CoQ10; and group B, treated with hyaluronic acid (HA). Eyedrops were administered 4 times daily for 3 months...
August 2, 2017: European Journal of Ophthalmology
https://www.readbyqxmd.com/read/28775329/transient-ingrowth-of-lymphatic-vessels-into-the-physiologically-avascular-cornea-regulates-corneal-edema-and-transparency
#8
Deniz Hos, Anne Bukowiecki, Jens Horstmann, Felix Bock, Franziska Bucher, Ludwig M Heindl, Sebastian Siebelmann, Philipp Steven, Reza Dana, Sabine A Eming, Claus Cursiefen
Lymphangiogenesis is essential for fluid homeostasis in vascularized tissues. In the normally avascular cornea, however, pathological lymphangiogenesis mediates diseases like corneal transplant rejection, dry eye disease, and allergy. So far, a physiological role for lymphangiogenesis in a primarily avascular site such as the cornea has not been described. Using a mouse model of perforating corneal injury that causes acute and severe fluid accumulation in the cornea, we show that lymphatics transiently and selectively invade the cornea and regulate the resolution of corneal edema...
August 3, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28771380/antioxidant-and-osmoprotecting-activity-of-taurine-in-dry-eye-models
#9
Claudio Bucolo, Annamaria Fidilio, Chiara Bianca Maria Platania, Federica Geraci, Francesca Lazzara, Filippo Drago
PURPOSE: To assess the protective effects of ophthalmic formulations based on taurine (TAU) and sodium hyaluronate (SH) in ocular surface. METHODS: Rabbit corneal epithelial cells [Statens Seruminstitut Rabbit Cornea (SIRC)] were subjected to oxidative stress (1 mM H2O2) and treated with the following formulations: 0.2% SH, 0.4% SH, 0.4% SH +0.5% TAU. Reactive oxygen species (ROS) were evaluated by commercial kit. Dry eye was induced by atropine sulfate and topical treatment was carried out with the following formulations: 0...
August 3, 2017: Journal of Ocular Pharmacology and Therapeutics
https://www.readbyqxmd.com/read/28771187/herbal-supplement-in-a-buffer-for-dry-eye-syndrome-treatment
#10
Hung-Chang Chen, Zhi-Yu Chen, Tsung-Jen Wang, Victor J Drew, Ching-Li Tseng, Hsu-Wei Fang, Feng-Huei Lin
Dry eye syndrome (DES) is one of the most common types of ocular diseases. There is a major need to treat DES in a simple yet efficient way. Artificial tears (AT) are the most commonly used agents for treating DES, but are not very effective. Herbal extractions of ferulic acid (FA), an anti-oxidant agent, and kaempferol (KM), an anti-inflammatory reagent, were added to buffer solution (BS) to replace ATs for DES treatment. The cytotoxicity and anti-inflammatory effects were examined in vitro by co-culture with human corneal epithelial cells (HCECs) to obtain the optimal concentration of KM and FA for treating HCECs...
August 3, 2017: International Journal of Molecular Sciences
https://www.readbyqxmd.com/read/28769593/resolution-of-pinguecula-related-dry-eye-disease-after-argon-laser-photocoagulation
#11
Pietro Emanuele Napoli, Raffaele Sanna, Claudio Iovino, Maurizio Fossarello
PURPOSE: To describe an unusual case of unilateral, chronic symptoms and signs of dry eye, and recurrent episodes of ocular irritation related to pinguecula, which were refractory to prior medical treatments, successfully treated with argon laser photocoagulation. METHODS: A 36-year-old man presented with an elevated yellowish mass on his conjunctiva in his left eye, which was associated with dry eye symptoms and general discomfort, such as "tightening sensation" and "stiffness"...
2017: International Medical Case Reports Journal
https://www.readbyqxmd.com/read/28759302/evaluation-of-clinical-efficacy-and-safety-of-a-novel-cyclosporin-a-nanoemulsion-in-the-treatment-of-dry-eye-syndrome
#12
Hyun Seung Kim, Tae-Im Kim, Jin Hyoung Kim, Kyung Chul Yoon, Joon Young Hyon, Ko Un Shin, Chul Young Choi
PURPOSE: Topical administration of the anti-inflammatory agent cyclosporin A (CsA) is recommended for long-term management of dry eye syndrome (DES), yet standard ophthalmic CsA preparations have been reported to be unstable. In this trial, the efficacy and safety of Clacier™ (based on a phase 3 study developed by Huons Co. Ltd.), a novel 0.05% CsA nanoemulsion formulation, are compared with those of the conventional Restasis(®) emulsion. METHODS: Patients with moderate-to-severe DES were randomly assigned to receive topical 0...
July 31, 2017: Journal of Ocular Pharmacology and Therapeutics
https://www.readbyqxmd.com/read/28752695/changes-in-tear-volume-after-3-diquafosol-treatment-in-patients-with-dry-eye-syndrome-an-anterior-segment-spectral-domain-optical-coherence-tomography-study
#13
Kwan Bok Lee, Kyung Min Koh, Young A Kwon, Sang Wroul Song, Byoung Yeop Kim, Jae Lim Chung
PURPOSE: To evaluate changes in the tear meniscus area and tear meniscus height over time in patients with dry eye syndrome, using anterior segment spectral-domain optical coherence tomography after the instillation of 3% diquafosol ophthalmic solution. METHODS: Sixty eyes from 30 patients with mild to moderate dry eye syndrome were included. Tear meniscus images acquired by anterior segment spectral-domain optical coherence tomography were analyzed using National Institutes of Health's image-analysis software (ImageJ 1...
August 2017: Korean Journal of Ophthalmology: KJO
https://www.readbyqxmd.com/read/28738415/monocarboxylate-transporters-mediate-fluorescein-uptake-in-corneal-epithelial-cells
#14
Yi-Chen Sun, Hau-Min Liou, Po-Ting Yeh, Wei-Li Chen, Fung-Rong Hu
Purpose: To determine the presence of monocarboxylate transporter (MCT) in human and rabbit corneal epithelium and its role in transcellular fluorescein transportation in the cornea. Methods: The presence of MCTs in human and rabbit corneal epithelium was determined by RT-PCR and immunohistochemistry. Intracellular fluorescein uptake experiment was performed using cultured human corneal epithelial cells (HCECs). The involvement of MCT in fluorescein uptake was determined by addition of MCT inhibitors to HCECs and acute dry eye model on New Zealand albino rabbits by spectrophotometry, corneal impression cytology, and external eye photographs...
July 1, 2017: Investigative Ophthalmology & Visual Science
https://www.readbyqxmd.com/read/28736344/tfos-dews-ii-clinical-trial-design-report
#15
REVIEW
Gary D Novack, Penny Asbell, Stefano Barabino, Michael V W Bergamini, Joseph B Ciolino, Gary N Foulks, Michael Goldstein, Michael A Lemp, Stefan Schrader, Craig Woods, Fiona Stapleton
The development of novel therapies for Dry Eye Disease (DED) is formidable, and relatively few treatments evaluated have been approved for marketing. In this report, the Subcommittee reviewed challenges in designing and conducting quality trials, with special reference to issues in trials in patients with DED and present the regulatory perspective on DED therapies. The Subcommittee reviewed the literature and while there are some observations about the possible reasons why so many trials have failed, there is no obvious single reason other than the lack of correlation between signs and symptoms in DED...
July 2017: Ocular Surface
https://www.readbyqxmd.com/read/28736343/tfos-dews-ii-management-and-therapy-report
#16
REVIEW
Lyndon Jones, Laura E Downie, Donald Korb, Jose M Benitez-Del-Castillo, Reza Dana, Sophie X Deng, Pham N Dong, Gerd Geerling, Richard Yudi Hida, Yang Liu, Kyoung Yul Seo, Joseph Tauber, Tais H Wakamatsu, Jianjiang Xu, James S Wolffsohn, Jennifer P Craig
The members of the Management and Therapy Subcommittee undertook an evidence-based review of current dry eye therapies and management options. Management options reviewed in detail included treatments for tear insufficiency and lid abnormalities, as well as anti-inflammatory medications, surgical approaches, dietary modifications, environmental considerations and complementary therapies. Following this extensive review it became clear that many of the treatments available for the management of dry eye disease lack the necessary Level 1 evidence to support their recommendation, often due to a lack of appropriate masking, randomization or controls and in some cases due to issues with selection bias or inadequate sample size...
July 2017: Ocular Surface
https://www.readbyqxmd.com/read/28735873/the-therapeutic-potential-of-purinergic-signalling
#17
REVIEW
Geoffrey Burnstock
This review is focused on the pathophysiology and therapeutic potential of purinergic signalling. A wide range of diseases are considered, including those of the central nervous system, skin, kidney, musculoskeletal, liver gut, lower urinary tract, cardiovascular, airways and reproductive systems, the special senses, infection, diabetes and obesity. Several purinergic drugs are already on the market, including P2Y12 receptor antagonists for stroke and thrombosis, P2Y2 receptor agonists for dry eye, A1 receptor agonists for supraventricular tachycardia...
July 20, 2017: Biochemical Pharmacology
https://www.readbyqxmd.com/read/28730936/an-industry-update-what-is-the-latest-news-in-therapeutic-delivery
#18
Iain Simpson
This Industry Update covers the period from 1 through 30 April 2017, and is based on information sourced from company press releases, scientific literature, patents and various news websites. Biogen expanded its portfolio of developmental drugs targeting neurological diseases by licensing a drug from Bristol-Myers Squibb which is currently under investigation for the treatment of progressive supranuclear palsy. Takeda announced a deal with NuBiyota focused on developing treatments for gastrointestinal disorders, based on the manipulation of microbes living in the gut...
July 2017: Therapeutic Delivery
https://www.readbyqxmd.com/read/28727604/preclinical-development-of-ebi-005-an-il-1-receptor-1-inhibitor-for-the-topical-ocular-treatment-of-ocular-surface-inflammatory-diseases
#19
Joseph Kovalchin, Bracken King, Allyson Masci, Elizabeth Hopkins, Jeremy Fry, Jay Hou, Christian Li, Kelly Tenneson, Steve Weber, Gary Wolfe, Kathy Collins, Eric S Furfine
OBJECTIVE: Topical interleukin (IL)-1 receptor (R)1 blockade is therapeutically active in reducing signs and symptoms of dry eye disease. Herein, we describe in vitro and in vivo nonclinical Investigational New Drug (IND)-enabling studies of EBI-005, a novel protein chimera of IL-1β and IL-1 receptor antagonist (IL-1Ra or anakinra) that potently binds IL-1R1 and blocks signaling. These studies provide an assessment of receptor affinity, drug bioavailability, immunogenic response, safety, and tolerability in mice and rabbits...
July 18, 2017: Eye & Contact Lens
https://www.readbyqxmd.com/read/28726777/humanin-g-hng-protects-age-related-macular-degeneration-amd-transmitochondrial-arpe-19-cybrids-from-mitochondrial-and-cellular-damage
#20
Sonali Nashine, Pinchas Cohen, Marilyn Chwa, Stephanie Lu, Anthony B Nesburn, Baruch D Kuppermann, M Cristina Kenney
Age-related macular degeneration (AMD) ranks third among the leading causes of visual impairment with a blindness prevalence rate of 8.7%. Despite several treatment regimens, such as anti-angiogenic drugs, laser therapy, and vitamin supplementation, being available for wet AMD, to date there are no FDA-approved therapies for dry AMD. Substantial evidence implicates mitochondrial damage and retinal pigment epithelium (RPE) cell death in the pathogenesis of AMD. However, the effects of AMD mitochondria and Humanin G (HNG), a more potent variant of the mitochondrial-derived peptide (MDP) Humanin, on retinal cell survival have not been elucidated...
July 20, 2017: Cell Death & Disease
keyword
keyword
97780
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"